LEVONORGESTREL - Generic Drug Details

What are the generic sources for levonorgestrel and what is the scope of patent protection?

Levonorgestrel is the generic ingredient in fourteen branded drugs marketed by Population Council, Wyeth Pharms Inc, Bayer Hlthcare, Medicines360, Aurobindo Pharma, Lupin Ltd, Novast Labs, Alvogen, Annora Pharma, Fdn Consumer, Glenmark Pharms Ltd, L Perrigo Co, Laboratoire Hra, Lotus Pharm Co Ltd, Naari Pte, Novel Labs Inc, Perrigo R And D, Watson Labs, Xiromed, and Sun Pharm, and is included in thirty-one NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Levonorgestrel has one hundred and thirteen patent family members in thirty-five countries.

There are twenty drug master file entries for levonorgestrel. Thirty-five suppliers are listed for this compound.

Summary for LEVONORGESTREL

International Patents:	113
US Patents:	7
Tradenames:	14
Applicants:	20
NDAs:	31
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	35
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	281
Patent Applications:	6,825
Drug Prices:	Drug price trends for LEVONORGESTREL
What excipients (inactive ingredients) are in LEVONORGESTREL?	LEVONORGESTREL excipients list
DailyMed Link:	LEVONORGESTREL at DailyMed

See drug prices for LEVONORGESTREL

See drug sales revenues for LEVONORGESTREL

Recent Clinical Trials for LEVONORGESTREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
Premier Research	PHASE2
HIV Prevention Trials Network	PHASE2

See all LEVONORGESTREL clinical trials

Pharmacology for LEVONORGESTREL

Drug Class	Progestin Progestin-containing Intrauterine System Progestin-containing Intrauterine Device
Physiological Effect	Inhibit Ovum Fertilization

Medical Subject Heading (MeSH) Categories for LEVONORGESTREL

Contraceptive Agents, Female

Contraceptives, Oral, Synthetic

Anatomical Therapeutic Chemical (ATC) Classes for LEVONORGESTREL

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03AD	Emergency contraceptives
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for LEVONORGESTREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	202246-001	Jun 5, 2015		DISCN	No	No
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013		RX	Yes	Yes	11,628,088		Y
Fdn Consumer	PLAN B	levonorgestrel	TABLET;ORAL	021045-002	Aug 24, 2006		DISCN	Yes	No
Perrigo R And D	LEVONORGESTREL	levonorgestrel	TABLET;ORAL	202334-001	Aug 20, 2014		OTC	No	No

Expired US Patents for LEVONORGESTREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Population Council	NORPLANT	levonorgestrel	IMPLANT;IMPLANTATION	019897-001	Dec 10, 1990	3,850,911
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013	7,252,839
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159-001	Jan 9, 2013	5,785,053
Population Council	NORPLANT	levonorgestrel	IMPLANT;IMPLANTATION	019897-001	Dec 10, 1990	3,959,322

International Patents for LEVONORGESTREL

Country	Patent Number	Title	Estimated Expiration
New Zealand	561952	An ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
World Intellectual Property Organization (WIPO)	2013009674
Japan	5390618
Poland	2352470

Supplementary Protection Certificates for LEVONORGESTREL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211

Market Dynamics and Financial Trajectory for Levonorgestrel

Last updated: February 19, 2026

Levonorgestrel is a widely used progestin hormone for contraception and emergency pregnancy prevention. Its market has expanded driven by regulatory, demographic, and technological factors, with sustained revenue growth projected over the next decade.

Market Overview

Levonorgestrel is integral to oral contraceptives, intrauterine devices, implants, and emergency contraceptive pills. The global market was valued at approximately USD 2.8 billion in 2022. It is expected to reach USD 4.5 billion by 2030, growing at an estimated CAGR of 6.1% (2023-2030). The compound annual growth rate (CAGR) reflects increasing adoption and expanding indications, buoyed by regulatory approvals and consumer demand.

Key Market Drivers

• Increasing contraceptive use: Rising awareness about family planning drives demand. The World Health Organization reports 63% of women aged 15-49 use some form of contraception globally.
• Emergency contraception acceptance: The recent approval of over-the-counter sales in multiple regions facilitates broader access.
• Product innovation: Development of low-dose formulations and novel delivery systems (e.g., implants) enhances adherence and expands market opportunities.
• Regulatory approvals: New formulations and expanded indications in emerging markets like Africa and Southeast Asia increase product penetration.

Market Segmentation

Segment	Key Insights	Revenue (2022)	Projected CAGR (2023-2030)
Oral contraceptives	Largest segment, driven by prescription and OTC sales.	USD 1.4B	5.8%
Intrauterine devices (IUDs)	Growing with increased acceptance due to safety profile.	USD 0.9B	6.5%
Emergency contraceptive pills	Rapid growth due to OTC accessibility and awareness.	USD 0.4B	8.0%
Implants and injections	Emerging segment, in early adoption phase.	USD 0.1B	7.2%

Competitive Landscape

Major pharmaceutical players include:

• Bayer AG: Markets the Levonorgestrel-containing intrauterine device Mirena and emergency contraceptive Plan B One-Step.
• HRA Pharma: Focuses on OTC emergency contraceptive brands like NorLevo.
• MediGene AG: Offers generic levonorgestrel formulations for oral and implantable systems.

Patent expiration timelines influence the generic entry, impacting pricing and margins. The primary patents for oral formulations in the U.S. expired between 2014-2017, increasing generic competition and compressing profit margins in developed markets.

Regulatory and Patent Environment

• The U.S. Food and Drug Administration (FDA) approved Plan B One-Step for OTC sale in 2013.
• European Medicines Agency (EMA) granted marketing authorization for various levonorgestrel formulations since 1998.
• Patent protections generally expired in key markets, enabling generics from 2014 onwards.
• Emerging markets lack patent protections or have shorter durations, resulting in lower prices and higher volume sales.

Financial Trajectory

Projected revenue growth is driven by:

• Market Expansion: Broadened access in emerging regions.
• Product Diversification: Introduction of new delivery systems.
• Regulatory Trends: Favorable approvals for OTC availability.

Year	Estimated Revenue (USD billion)	Market Share of Top Players	Avg. Price per Unit (USD)
2022	2.8	Bayer (40%), HRA Pharma (15%)	10
2025	3.8	Bayer (35%), generics (20%)	8
2030	4.5	Generics (50%), Innovators (20%)	7

Margins for generic manufacturers are compressed due to price erosion, but sales volume compensates for lower per-unit revenue. Innovative formulations and branded products retain higher margins but face patent cliffs.

Conclusion

Levonorgestrel’s market is characterized by steady growth, driven by demographic trends, regulatory changes, and product innovation. Volume-driven growth in generics and expanding OTC sales support revenue increase. Price competition and patent expirations pose risks of margin compression for branded products but open opportunities for generic manufacturers and biosimilar entry.

Key Takeaways

• Revenue is projected to grow from USD 2.8 billion in 2022 to USD 4.5 billion in 2030.
• CAGR estimates range from 5.8% in oral contraceptives to 8.0% in emergency contraceptives.
• Patent expirations have catalyzed generic entry, influencing pricing strategies.
• Emerging markets offer substantial growth potential due to increasing contraceptive use and regulatory shifts.
• Product innovation and OTC availability are critical to capturing additional market share.

FAQs

1. How do patent expirations impact levonorgestrel market revenue?
Patent expirations enable generic manufacturers to enter markets, increasing competition and driving down prices. Revenue for brand-name products declines unless offset by new formulations or indications.

2. What regulatory trends could influence future sales?
Expanding OTC availability, especially for emergency contraceptives, increases access, thereby boosting sales. Regulatory approvals in emerging markets further open revenue streams.

3. Which regions show the highest growth potential?
Africa, Southeast Asia, and Latin America demonstrate high growth potential due to rising contraceptive adoption, expanding healthcare infrastructure, and regulatory liberalization.

4. How does product innovation affect market dynamics?
Developing new delivery systems (e.g., implants) and formulations (lower doses, combination products) can extend product lifecycle and differentiate offerings, impacting market share.

5. What competitive strategies are prevalent?
Key strategies include patent filing, expanding OTC access, developing biosimilars, and offering cost-effective generics to gain market share in mature and emerging segments.

References

[1] Grand View Research. (2023). Levonorgestrel Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Contraceptive Market Trends.
[3] EMA. (2022). Summary of Product Characteristics for Levonorgestrel.
[4] FDA. (2013). Approval Letter for Plan B One-Step.